These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 39241743)
1. Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases. Baker DJ; June CH Cell; 2024 Sep; 187(18):4826-4828. PubMed ID: 39241743 [TBL] [Abstract][Full Text] [Related]
2. Highlight of 2023: CAR T cells driving precision therapy for autoimmune disease. Lee AY; Reed JH Immunol Cell Biol; 2024 Jul; 102(6):437-440. PubMed ID: 38693765 [TBL] [Abstract][Full Text] [Related]
3. Off-the-shelf CAR T cells for refractory autoimmunity. Papatriantafyllou M Nat Rev Rheumatol; 2024 Sep; 20(9):527. PubMed ID: 39075289 [No Abstract] [Full Text] [Related]
4. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells. Morgan MA; Büning H; Sauer M; Schambach A Front Immunol; 2020; 11():1965. PubMed ID: 32903482 [TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospects. Zhang PF; Xie D; Li Q Immunotherapy; 2020 Sep; 12(13):1021-1034. PubMed ID: 32727249 [TBL] [Abstract][Full Text] [Related]
6. Frontiers in CAR-T cell therapy for autoimmune diseases. Li YR; Lyu Z; Chen Y; Fang Y; Yang L Trends Pharmacol Sci; 2024 Sep; 45(9):839-857. PubMed ID: 39147651 [TBL] [Abstract][Full Text] [Related]
7. CAR T-Cell Therapy in Autoimmune Disease. Reply. Müller F; Mackensen A; Schett G N Engl J Med; 2024 May; 390(17):1631-1632. PubMed ID: 38692300 [No Abstract] [Full Text] [Related]
8. Is There a Place for Chimeric Antigen Receptor-T Cells in the Treatment of Chronic Autoimmune Rheumatic Diseases? Orvain C; Boulch M; Bousso P; Allanore Y; Avouac J Arthritis Rheumatol; 2021 Nov; 73(11):1954-1965. PubMed ID: 34042325 [TBL] [Abstract][Full Text] [Related]
9. CAR T-Cell Therapy in Autoimmune Disease. Howard JF; Vu T; Mozaffar T N Engl J Med; 2024 May; 390(17):1629-1631. PubMed ID: 38692299 [No Abstract] [Full Text] [Related]
10. CAR T-Cell Therapy in Autoimmune Disease. Merkt W; Lorenz HM; Schmitt M N Engl J Med; 2024 May; 390(17):1628-1629. PubMed ID: 38692297 [No Abstract] [Full Text] [Related]
11. CAR T-Cell Therapy in Autoimmune Disease. De Benedetti F; Diomedi Camassei F; Locatelli F N Engl J Med; 2024 May; 390(17):1629. PubMed ID: 38692298 [No Abstract] [Full Text] [Related]
12. Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies. Feucht J; Abou-El-Enein M Mol Ther; 2020 Oct; 28(10):2108-2110. PubMed ID: 32841587 [No Abstract] [Full Text] [Related]
13. [Not Available]. Comte D Rev Med Suisse; 2024 Jun; 20(877):1139. PubMed ID: 38836401 [No Abstract] [Full Text] [Related]
14. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy. Ghassemi S; Milone MC J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011 [TBL] [Abstract][Full Text] [Related]
15. Advances in off-the-shelf CAR T-cell therapy. Benjamin R Clin Adv Hematol Oncol; 2019 Mar; 17(3):155-157. PubMed ID: 30969953 [No Abstract] [Full Text] [Related]
16. Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease. Daamen AR; Lipsky PE Ann Rheum Dis; 2024 May; 83(6):696-699. PubMed ID: 38637134 [TBL] [Abstract][Full Text] [Related]
17. Engineering CAR-T Cells for Next-Generation Cancer Therapy. Hong M; Clubb JD; Chen YY Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779 [TBL] [Abstract][Full Text] [Related]
18. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells. Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A Front Immunol; 2018; 9():1717. PubMed ID: 30108584 [TBL] [Abstract][Full Text] [Related]
19. Dawn of CAR-T cell therapy in autoimmune diseases. Liu Y; Dong M; Chu Y; Zhou L; You Y; Pang X; Yang S; Zhang L; Chen L; Zhu L; Xiao J; Wang W; Qin C; Tian D Chin Med J (Engl); 2024 May; 137(10):1140-1150. PubMed ID: 38613216 [TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma. Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]